Statin initiation after ASCVD events was tied to better long-term survival in dialysis patients
Patients receiving dialysis have long sat outside the strongest randomized statin evidence, especially after a new atherosclerotic cardiovascular disease event. A large French registry analysis now fills part of that gap with real-world data suggesting that statin therapy after an ASCVD event is associated with a meaningful survival advantage in CKD G5D, the kidney failure population treated by dialysis.
The cohort included 5,534 adults, with a median age of 75 years and 67% male. Follow-up extended across 10 years, allowing the investigators to capture effects that are easy to miss in shorter studies. In a population with very high competing cardiovascular risk, even modest shifts in survival carry clinical weight.
The signal was not immediate and it was not trivial. The survival curves separated over time, reaching their largest absolute difference at year four, when mortality differed by 6.2 percentage points. Relative risk also favored statin initiation, with a value of 0.88. In dialysis care, where many patients have limited physiologic reserve and a heavy burden of prior vascular disease, that degree of separation points to a clinically relevant secondary-prevention effect rather than a purely statistical artifact.
Real-world methods targeted a secondary-prevention question randomized trials left open
The analysis used the French Renal Epidemiology and Information Network registry, linked with the French national healthcare system database from 2010 through 2023. Investigators applied a landmark-based observational design informed by the target trial framework, which is intended to make nonrandomized data approximate the structure of a randomized comparison as closely as possible. In practical terms, that approach helps reduce bias introduced when treatment decisions are made after the clinical event of interest.
Adults with dialysis-dependent kidney failure who experienced an ASCVD event formed the study population. Statin initiators were compared with non-initiators, and inverse probability of treatment weighting was used to balance baseline characteristics between the two groups. The main outcome was all-cause mortality, assessed through relative and absolute risk difference, with life expectancy estimated using delta restricted mean survival time, or dRMST.
This design directly addresses a stubborn evidence gap. Statins clearly lower cardiovascular risk in the general population, yet prior randomized trials in kidney disease mixed primary and secondary prevention populations and excluded patients with recent cardiovascular events. Those exclusions matter because the highest-risk patients are often the ones most likely to benefit from aggressive lipid-lowering after plaque rupture, myocardial infarction, stroke, or another ASCVD presentation.
Survival gains accumulated gradually over years rather than days
The most clinically important finding is the time course of benefit. The survival curves did not diverge sharply in the first few months; instead, the effect unfolded across years, reaching its maximum absolute separation at year four. That pattern fits the biology of statin therapy. These drugs do more than lower LDL cholesterol. They also stabilize atherosclerotic plaque, reduce inflammatory activity within the arterial wall, and may blunt the recurrence of downstream ischemic events that drive mortality in a dialysis population already exposed to vascular stress.
At five years, statin initiation was associated with a mean survival gain of 69 days. By 10 years, the estimated gain reached 135 days. Those numbers are not abstract in a cohort with a median age of 75 years and high competing mortality risk. In secondary prevention, a few additional months of survival can mean time free from hospitalization, time at home, and time with preserved function, provided the treatment is tolerated and the benefit is real.
The absolute risk difference at the point of maximal separation was -6.2%, with a 95% confidence interval from -10.2 to -2.2. The relative risk of 0.88, with a 95% confidence interval from 0.81 to 0.96, reinforces the same direction of effect. The two measures tell a complementary story: the relative effect is modest, but the absolute effect becomes meaningful because the baseline risk is so high.
Safety signals did not worsen with statin use in the dialysis cohort
Safety deserves special attention in dialysis patients because muscle toxicity and hepatic injury are the adverse effects clinicians fear most when deciding whether to start a statin after an ASCVD event. Here, no difference emerged between groups for hospitalizations related to rhabdomyolysis or toxic hepatitis.
That absence of a detectable safety penalty is important, but it should be read carefully. The study was not designed to prove that rare adverse events never occur. It does show that, in this large registry cohort, statin initiation was not accompanied by a measurable rise in serious toxicity severe enough to require hospitalization. For a frail population often exposed to polypharmacy, that matters at the bedside.
The combination of survival benefit and neutral safety findings strengthens the case for considering statins in secondary prevention after ASCVD among people on dialysis. It also gives clinicians a more concrete evidence base when weighing treatment in older adults whose absolute cardiovascular risk is extreme but whose noncardiovascular mortality risk remains high.
What the registry can and cannot answer
This evidence is observational, and no amount of statistical adjustment can fully eliminate confounding by indication or residual differences between patients who start treatment and those who do not. Healthier patients may be more likely to receive a statin, and clinicians may selectively prescribe therapy to those perceived as more stable. Even with inverse probability weighting and a target-trial style design, those limitations remain part of the interpretation.
The study also focuses on all-cause mortality rather than isolating cardiovascular deaths, so the precise pathway behind the survival gain cannot be pinned down from these data alone. Still, the biology of statins, the timing of benefit, and the direction of the effect all support a plausible secondary-prevention mechanism.
For now, the most defensible reading is straightforward: in dialysis patients who have already had an ASCVD event, starting a statin was associated with better long-term survival and no detected increase in major toxicity-related hospitalizations. The next unanswered question is not whether the signal exists in this cohort, but how best to define which dialysis patients derive the greatest absolute benefit and how soon after an event treatment should begin.